Retatrutide
Retatrutide (LY3437943, GIP/GLP-1/glucagon triple receptor agonist peptide) · ≥98% (HPLC)
Retatrutide (LY3437943) is a synthetic 39-residue lipidated triple-agonist peptide used as a characterized reference material for in-vitro study of GIPR, GLP-1R, and GCGR signaling. For research use only.
More in Metabolic signaling
Tirzepatide
Direct-lab pricing · up to 50% below comparable retail listings
Tirzepatide is a synthetic 39-residue lipidated dual GIP/GLP-1 receptor agonist peptide supplied as a characterized reference material for in-vitro receptor and analytical research. For Research Use Only. Not for human or veterinary use.
Semaglutide
Direct-lab pricing · up to 50% below comparable retail listings
Semaglutide is a synthetic 31-residue lipidated GLP-1 receptor agonist peptide supplied as a characterized reference material for in-vitro receptor and analytical research. For Research Use Only. Not for human or veterinary use.
AOD9604
Direct-lab pricing · up to 50% below comparable retail listings
AOD9604 is a synthetic 16-residue fragment of human growth hormone (residues 176-191) supplied as a characterized reference material for in-vitro lipid-metabolism research, independent of the GH/IGF-1 axis. Research Use Only.
Research profile & documentation
- Why researchers study it
- Studied in receptor-pharmacology and structural-biology research as a single-molecule probe that engages three class-B GPCRs (GIPR, GLP-1R, GCGR), enabling comparative in-vitro investigation of incretin- and glucagon-receptor activation and signaling bias.
- Mechanism themes in research
- Triple agonism across GIPR, GLP-1R, and GCGR (class B GPCRs)GIP-based 39-residue peptide backbone re-engineered for cross-receptor recognitionNon-coded residues (Aib2, αMeLeu13, Aib20) altering backbone conformation and proteolytic stability in vitroC20 fatty-diacid (γGlu/AEEA-linked) side chain enabling albumin association studied in PK/structural contexts
- What the evidence does not establish
- Published references are in-vitro or pre-clinical and describe research context only. They do not establish safety, efficacy, or any outcome in humans or animals, and Helix makes no such claims.
- Quality markers
- ≥98% (HPLC)MS identityLot COACold-chain
- What ships
- The sealed lot-controlled vial, a measured ampoule of bacteriostatic water, and a printed handling & reconstitution card — plus the per-lot COA. Everything to prepare it, in one box.
Retatrutide (LY3437943) is a synthetic, lipid-conjugated 39-amino-acid peptide that acts as a unimolecular triple agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). It is supplied as a research-use-only reference material for in-vitro and structural studies of these class B GPCRs. Reported chemistry: molecular formula C₂₂₁H₃₄₂N₄₆O₆₈, molecular weight ≈ 4731.3 g/mol, CAS 2381089-83-2.
Analytical identity
Retatrutide is cataloged under CAS 2381089-83-2 with the molecular formula C₂₂₁H₃₄₂N₄₆O₆₈ and a molecular weight of approximately 4731.3 g/mol. It is a 39-residue peptide built on a GIP-derived backbone, supplied as a lyophilized powder at ≥98% (HPLC) for use as an analytical and experimental reference standard. Chemistry values are drawn from public PubChem/literature records and should be independently confirmed against a certificate of analysis.
Structure and modifications
The sequence incorporates three non-coded residues — 2-aminoisobutyric acid at positions 2 and 20 (Aib2, Aib20) and α-methyl-L-leucine at position 13 (αMeLeu13) — together with a C20 fatty-diacid moiety attached via a γGlu/AEEA linker to a lysine side chain, and a C-terminal amide. These features are described in the literature as influencing backbone conformation, proteolytic resistance, and albumin association in in-vitro and pharmacokinetic study contexts.
| Full name | Retatrutide (LY3437943, GIP/GLP-1/glucagon triple receptor agonist peptide) |
| Research theme | Metabolic signaling |
| CAS number | 2381089-83-2 |
| Molecular formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular weight | 4731.3 g/mol |
| Purity | ≥98% (HPLC) |
| Physical form | Lyophilized powder |
| Storage | −20 °C, desiccated, protected from light |
Sequence
Reported research areas
- Class B GPCR receptor-pharmacology and binding assays
- Cryo-EM / structural characterization of peptide-receptor complexes
- Comparative incretin and glucagon receptor signaling studies
- Analytical reference standard for peptide identity and purity (HPLC/MS)
Credible sources
- PubChem — Retatrutide (search)
- PubMed — Retatrutide (search)
- Structural insights into the triple agonism at GLP-1R, GIPR and GCGR (PMC11255275)
COA with every lot
Each Retatrutide lot is characterized by reversed-phase HPLC for purity and by mass spectrometry for identity, then documented in a per-lot Certificate of Analysis. Unique lot numbers tie the vial back to its synthesis batch and analytical data.
- RP-HPLC purity result (≥98% (HPLC))
- Mass-spectrometry identity confirmation
- Appearance, molecular weight, and storage
- Lot number and testing status
Specimen Certificate of Analysis
| Product | Retatrutide (reference) |
| Lot | HXR-2406-102 |
| Purity (RP-HPLC) | 98%+ |
| Identity (MS) | Confirmed · 4731.3 g/mol |
| Appearance | Lyophilized powder |
| Storage | −20 °C, desiccated |
Representative document. Each lot has its own COA — these are quality documents, not medical claims.
Loading verified reviews…
Reviews come only from buyers we can match to a real order, and each is moderated before it appears. We never publish fabricated or incentivized reviews.